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Background: The preclinical stage of systolic heart failure (HF), known as
asymptomatic left ventricular dysfunction (ALVD), is diagnosed only by
echocardiography, frequent in the general population and leads to a high risk
of developing severe HF. Large scale screening for ALVD is a difficult task
and represents a major unmet clinical challenge that requires the determination
of ALVD biomarkers.
Methodology/Principal Findings: 294 individuals were screened by
echocardiography. We identified 9 ALVD cases out of 128 subjects with car-
diovascular risk factors. White blood cell gene expression profiling was per-
formed using pangenomic microarrays. Data were analyzed using principal
component analysis (PCA) and Significant Analysis of Microarrays (SAM).
To build an ALVD classifier model, we used the nearest centroid classifica-
tion method (NCCM) with the ClaNC software package. Classification perfor-
mance was determined using the leave-one-out cross-validation method.
Blood transcriptome analysis provided a specific molecular signature for
ALVD which defined a model based on 7 genes capable of discriminating
ALVD cases. Analysis of an ALVD patients validation group demonstrated
that these genes are accurate diagnostic predictors for ALVD with 87% accu-
racy and 100% precision. Furthermore, Receiver Operating Characteristic
curves of expression levels confirmed that 6 out of 7 genes discriminate for
left ventricular dysfunction classification.
Conclusions/Significance: These targets could serve to enhance the ability
to efficiently detect ALVD by general care practitioners to facilitate preemp-
tive initiation of medical treatment preventing the development of HF.
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Background. Acute heart failure may induce increased level of plasmatic
troponin. The aim of this study was to assess the diagnostic and prognostic
value of troponin I in acute cardiogenic pulmonary edema.
Methods. We studied 619 consecutive patients admitted to our institution
for acute cardiogenic pulmonary edema during a six years period (from Jan-
uary 2003 to December 2009). Baseline characteristics, ECG, biological
markers (including troponin I) and in-hospital mortality were systematically
analyzed. Patients with increased troponin underwent coronary angiography.
Results. Prevalence of increased plasmatic troponin level was 48%
(n=297) of acute pulmonary edema. Diabetes (p=0.01), ECG signs of myocar-
dial ischemia (p<0.0001) and chest pain (p<0.0001) were more frequently
found in patients with increased levels of troponin. Among these patients, a
coronary artery disease was only diagnosed in 166 patients (56%), but was
more frequently diagnosed in patients with chest pain (72%, p=0.01) and in
patients with previous history of CAD (81%, p<0.01). The duration of hospi-
talization and the in-hospital mortality rate were significantly higher in
patients with increased plasmatic troponin level (mortality: 8.4% versus 3.1%;
p<0.004). In multivariate analysis, increased plasmatic troponin level was
independently related to death (OR=2.3, 95% CI: 1.3-20.1, p=0.02).
Background. Increased plasmatic troponin level is found in 48% of
patients presenting with acute pulmonary edema, but is related to coronary
artery disease in only 56%. Interestingly, increased plasmatic troponin level is
related to an independent increased risk of mortality in patients with acute pul-
monary edema.
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Aims: Systolic blood pressure (SBP) level is positively correlated with sur-
vival in chronic systolic heart failure (CHF) and negatively with arterial
hypertension disease. A high level of blood pressure variability (BPV) repre-
sents, especially in arterial hypertension disease, a stronger cardiovascular
risk. The aim of our study was to evaluate the pronostic impact of BPV level
by ambulatory monitoring blood pressure (AMBP) in CHF.
Methods: We retrospectively collected AMBP of 288 patients (60±12
years, males 227(79%)) hospitalized for CHF (47% NYHA III&IV, LVEF
28±9%) between 1999 and 2006. After retrieving characteristics, such as dia-
betes (21%), Hypertension (43%) or etiology (ischemic 45%), follow up was
realized retrospectively using physician, patient or family phone contact
during 2010. The composite outcome was defined by all causes of death and/
or heart transplant. Logrank mantel cox (qualitative), cox model (quantitative)
and cox stepwise logistic regression were used to perform univariate (table 2)
and multivariate analysis factors on outcome.
Results: During a mean follow up of 7 years, the composite outcome was
observed for 71 (32.2 %) patients (6 heart transplants and 65 deaths). High
SBP (mean 110±15), DBP (68±10), systolic BPV daytime (23±9) levels are
positively correlated with survival in univariate analysis. Multivariate analysis
included age, diabetes, BMI, NYHA, systolic BPV daytime, (SBP daytime
and nighttime), DBP (daytime, nightime), Pulse pressure (daytime nighttime)
and worse congestive state at the admission. Thus, NYHA class III/IV
(RR=5.1, p<0.01) and systolic BPV daytime (RR=0.963, p<0.03) were found
to be the two independent factors of survival. Arbitrary poor pronostic value
cut off at <19 mmHg was chosen to represent impact of systolic BPV daytime
on cumulative outcome (RR=1.65, 95 % IC 1-2.7; p<0.04).
Conclusion: In this population of 288 patients with CHF, a high level of
BPV daytime is an independent factor of survival.
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Objective: To determine whether sleep-disordered breathing (SDB)
severity, pattern, polygraphic variables and their ventilatory treatment in
chronic heart failure (CHF) were associated with adverse CHF outcomes.
Background: SDB are frequent in CHF. The relationships bewteen SDB
and outcome in CHF are unknow.
Methods: 384 CHF patients with LVEF <45% were assessed by a polyg-
raphy in our CHF clinic. Ventilatory treatment was started according to SDB
severity. Combined endpoint was death, heart tranplant and ventricular assit
device implant.
Results: Of the 384 CHF, their mean (SD) age was 59+/–13, LVEF was
299 and 82%% were men. Obstructive sleep apnoea (OSA), central sleep
apnoea (CSA) and Cheyne-Stockes respiration (CSR) prevalences were 62%,
26% and 29%. Primary endpoint was observed in 31%. Mean (SD) follow-up
for survivors was 47+/– 25months. Moderate (5.h-120.h-1), OSA and CSA
had a similar bad prognostic compared to patients without SDB (respectively
p=0.036; p=0.003). 31% of the SDB patients received a ventilatory treatment
of whom 98% had severe SDB. Treated SDB had a better outcome than
untreated severe SDB after adjustement for cofounding factors (p=0.031; HR:
